Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Tomasz Beer

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Disease Progression

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
38
Garzotto, Mark
21
Ryan, Christopher
20
Henner, David
17
Mori, Motomi
12
Eilers, Kristine
11
Higano, Celestia
11
Wersinger, Emily
8
Lowe, Bruce
7
Lemmon, Dianne
7
Myrthue, Anne
7
Hussain, Maha
7
Bland, Lisa
6
Dreicer, Robert
6
Petrylak, Daniel
5
Crawford, David

Sign-in to see all Coauthors

Publications

TOP 3
Blanke C D; Beer T M; Todd K; Mori M; Stone M; Lopez C
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer.
Rosenberg Jonathan E; Ryan Charles J; Weinberg Vivian K; Smith David C; Hussain Maha; Beer Tomasz M; Ryan Christopher W; Mathew Paul; Pagliaro Lance C; Harzstark Andrea L; Sharib Jeremy; Small Eric J
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Qian David Z; Huang Chung-Ying; O'Brien Catherine A; Coleman Ilsa M; Garzotto Mark; True Lawrence D; Higano Celestia S; Vessella Robert; Lange Paul H; Nelson Peter S; Beer Tomasz M
Prostate cancer-associated gene expression alterations determined from needle biopsies.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Tomasz Beer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Blanke C D; Beer T M; Todd K; Mori M; Stone M; Lopez C
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer.
Investigational new drugs 2009;27(4):374-8.
2009: Rosenberg Jonathan E; Ryan Charles J; Weinberg Vivian K; Smith David C; Hussain Maha; Beer Tomasz M; Ryan Christopher W; Mathew Paul; Pagliaro Lance C; Harzstark Andrea L; Sharib Jeremy; Small Eric J
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(17):2772-8.
2009: Qian David Z; Huang Chung-Ying; O'Brien Catherine A; Coleman Ilsa M; Garzotto Mark; True Lawrence D; Higano Celestia S; Vessella Robert; Lange Paul H; Nelson Peter S; Beer Tomasz M
Prostate cancer-associated gene expression alterations determined from needle biopsies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3135-42.
2009: Tran Chris; Ouk Samedy; Clegg Nicola J; Chen Yu; Watson Philip A; Arora Vivek; Wongvipat John; Smith-Jones Peter M; Yoo Dongwon; Kwon Andrew; Wasielewska Teresa; Welsbie Derek; Chen Charlie Degui; Higano Celestia S; Beer Tomasz M; Hung David T; Scher Howard I; Jung Michael E; Sawyers Charles L
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Science (New York, N.Y.) 2009;324(5928):787-90.
2009: Morris Michael J; Basch Ethan M; Wilding George; Hussain Maha; Carducci Michael A; Higano Celestia; Kantoff Philip; Oh William K; Small Eric J; George Daniel; Mathew Paul; Beer Tomasz M; Slovin Susan F; Ryan Charles; Logothetis Christopher; Scher Howard I
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
Clinical genitourinary cancer 2009;7(1):51-7.
2009: Farhat Ghada N; Taioli Emanuela; Cauley Jane A; Zmuda Joseph M; Orwoll Eric; Bauer Douglas C; Wilt Timothy J; Hoffman Andrew R; Beer Tomasz M; Shikany James M; Daniels Nicholas; Chan June; Fink Howard A; Barrett-Connor Elizabeth; Parsons J Kellogg; Bunker Clareann H;
The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) Study.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(1):148-54.
2009: Schnadig Ian D; Beer Tomasz M
Optimal timing of chemotherapy in androgen independent prostate cancer.
Urologic oncology 2009;27(1):97-100.
2008: Chan Joseph S; Beer Tomasz M; Quinn David I; Pinski Jacek K; Garzotto Mark; Sokoloff Mitchell; Dehaze Daniel R; Ryan Christopher W
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
BJU international 2008;102(11):1601-6.
2008: Schnadig Ian D; Fromme Erik K; Loprinzi Charles L; Sloan Jeff A; Mori Motomi; Li Hong; Beer Tomasz M
Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer.
Cancer 2008;113(8):2205-14.
2008: Beer Tomasz M; Goldman Bryan; Synold Timothy W; Ryan Christopher W; Vasist Lakshmi S; Van Veldhuizen Peter J; Dakhil Shaker R; Lara Primo N; Drelichman Anibal; Hussain Maha H A; Crawford E David
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Clinical genitourinary cancer 2008;6(2):103-9.
2008: Myrthue Anne; Rademacher Brooks L S; Pittsenbarger Janet; Kutyba-Brooks Bozena; Gantner Marin; Qian David Z; Beer Tomasz M
The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3562-70.
2008: Beer Tomasz M; Lalani Alshad S; Lee Stella; Mori Motomi; Eilers Kristine M; Curd John G; Henner W David; Ryan Christopher W; Venner Peter; Ruether J Dean; Chi Kim N;
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Cancer 2008;112(11):2377-83.
2008: Beer Tomasz M; Goldman Bryan; Nichols Craig R; Petrylak Daniel P; Agarwal Manoj; Ryan Christopher W; Crawford E David;
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Clinical genitourinary cancer 2008;6(1):36-9.
2008: Ciszewski Aleksandra; Shackleton Dustin; Beer Tomasz M
Long-term remission of metastatic small cell carcinoma of the prostate.
Urology 2008;71(3):546.e3-4.
2008: Scher Howard I; Halabi Susan; Tannock Ian; Morris Michael; Sternberg Cora N; Carducci Michael A; Eisenberger Mario A; Higano Celestia; Bubley Glenn J; Dreicer Robert; Petrylak Daniel; Kantoff Philip; Basch Ethan; Kelly William Kevin; Figg William D; Small Eric J; Beer Tomasz M; Wilding George; Martin Alison; Hussain Maha;
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1148-59.
2008: Ross Robert W; Beer Tomasz M; Jacobus Susanna; Bubley Glenn J; Taplin Mary-Ellen; Ryan Christopher W; Huang Jiaoti; Oh William K;
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Cancer 2008;112(3):521-6.
2008: Beer Tomasz M; Ryan Christopher W; Venner Peter M; Petrylak Daniel P; Chatta Gurkamal S; Ruether J Dean; Chi Kim N; Young James; Henner W David;
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Cancer 2008;112(2):326-30.
2007: Beer Tomasz M; Higano Celestia S; Saleh Mansoor; Dreicer Robert; Hudes Gary; Picus Joel; Rarick Mark; Fehrenbacher Louis; Hannah Alison L
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
Investigational new drugs 2007;25(6):565-70.
2007: Basch Ethan M; Somerfield Mark R; Beer Tomasz M; Carducci Michael A; Higano Celestia S; Hussain Maha H A; Scher Howard I;
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5313-8.
2007: Beer Tomasz M; Ryan Christopher W
The hazards of intermediate endpoints.
Cancer 2007;110(9):1877-9.
2007: Huang Chung-Ying; Beer Tomasz M; Higano Celestia S; True Lawrence D; Vessella Robert; Lange Paul H; Garzotto Mark; Nelson Peter S
Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5825-33.
2007: Ryan Charles J; Beer Tomasz M
Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design.
The Journal of urology 2007;178(3 Pt 2):S25-9.
2007: Kantoff Philip W; Beer Tomasz M; D'Amico Anthony V; Dipaola Robert S; Eisenberger Mario A; Hussain Maha H A; Kelly William Kevin; Mathew Paul; Morris Michael J; Ryan Charles J; Sandler Howard M; Thompson Ian M; Carroll Peter R
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference.
The Journal of urology 2007;178(3 Pt 2):S5-8; quiz S4.
2007: Montgomery R Bruce; Nelson Peter S; Lin Daniel; Ryan Christopher W; Garzotto Mark; Beer Tomasz M
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Cancer 2007;110(5):996-1002.
2007: Lagunova Zoya; Porojnicu Alina Carmen; Dahlback Arne; Berg Jens Petter; Beer Tomasz M; Moan Johan
Prostate cancer survival is dependent on season of diagnosis.
The Prostate 2007;67(12):1362-70.
2007: Ryan Christopher W; Goldman Bryan H; Lara Primo N; Mack Philip C; Beer Tomasz M; Tangen Catherine M; Lemmon Dianne; Pan Chong-Xian; Drabkin Harry A; Crawford E David;
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3296-301.
2007: Ryan Christopher W; Huo Dezheng; Stallings James W; Davis Ronald L; Beer Tomasz M; McWhorter Laura T
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Urology 2007;70(1):122-6.
2007: Beer Tomasz M; Bergenstock Misty; Birt Karlee; Higano Celestia S
Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.
Clinical genitourinary cancer 2007;5(5):329-33.
2007: Spurgeon Stephen E F; Mongoue-Tchokote Solange; Collins Lauren; Priest Ryan; Hsieh Yi-Ching; Peters Laura M; Beer Tomasz M; Mori Motomi; Garzotto Mark
Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Urology 2007;69(5):931-5.
2007: Kibel Adam S; Rosenbaum Eli; Kattan Michael W; Picus Joel; Dreicer Robert; Klein Eric A; Chatta Gurkamal S; Nelson Joel B; DiPaola Robert S; Roth Bruce J; Cookson Michael S; Wilding George; Jarrard David F; Beer Tomasz M; Ryan Christopher W; Petrylak Daniel P; Benson Mitchell C; Partin Alan W; Garrett-Mayer Elizabeth; Eisenberger Mario A
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
The Journal of urology 2007;177(5):1777-81.
2007: Graff Julie N; Mori Motomi; Li Hong; Garzotto Mark; Penson David; Potosky Arnold L; Beer Tomasz M
Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
The Journal of urology 2007;177(4):1307-12.
2007: Beer Tomasz M; Javle Milind M; Ryan Christopher W; Garzotto Mark; Lam Gilbert N; Wong Alvin; Henner W David; Johnson Candace S; Trump Donald L
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.
Cancer chemotherapy and pharmacology 2007;59(5):581-7.
2007: Beer Tomasz M; Ryan Christopher W; Venner Peter M; Petrylak Daniel P; Chatta Gurkamal S; Ruether J Dean; Redfern Charles H; Fehrenbacher Louis; Saleh Mansoor N; Waterhouse David M; Carducci Michael A; Vicario Daniel; Dreicer Robert; Higano Celestia S; Ahmann Frederick R; Chi Kim N; Henner W David; Arroyo Alan; Clow Fong W;
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):669-74.
2007: Sternberg Cora N; Krainer Michael; Oh William K; Bracarda Sergio; Bellmunt Joaquim; Ozen Haluk; Zlotta Alexandre; Beer Tomasz M; Oudard Stephane; Rauchenwald Michael; Skoneczna Iwona; Borner Markus M; Fitzpatrick John M
The medical management of prostate cancer: a multidisciplinary team approach.
BJU international 2007;99(1):22-7.
2006: Lycette Jennifer L; Bland Lisa B; Garzotto Mark; Beer Tomasz M
Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
Clinical genitourinary cancer 2006;5(3):198-205.
2006: Beer Tomasz M; Venner Peter M; Ryan Christopher W; Petrylak Daniel P; Chatta Gurkamal; Dean Ruether J; Chi Kim N; Curd John G; DeLoughery Thomas G
High dose calcitriol may reduce thrombosis in cancer patients.
British journal of haematology 2006;135(3):392-4.
2006: Taylor Brent C; Wilt Timothy J; Fink Howard A; Lambert Lori C; Marshall Lynn M; Hoffman Andrew R; Beer Tomasz M; Bauer Douglas C; Zmuda Joseph M; Orwoll Eric S;
Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study.
Urology 2006;68(4):804-9.
2006: Beer Tomasz M; Ryan Christopher; Bhat Gajanan; Garnick Marc;
Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
Anti-cancer drugs 2006;17(9):1075-9.
2006: Lycette Jennifer L; Luoh Shiuh-Wen; Beer Tomasz M; Deloughery Thomas G
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Breast cancer research and treatment 2006;99(3):249-55.
2006: Ganzini Linda; Beer Tomasz M; Brouns Matthew C
Views on physician-assisted suicide among family members of Oregon cancer patients.
Journal of pain and symptom management 2006;32(3):230-6.
2006: Ryan Christopher W; Huo Dezheng; Demers Laurence M; Beer Tomasz M; Lacerna Leo V
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
The Journal of urology 2006;176(3):972-8; discussion 978.
2006: Beer Tomasz M; Tangen Catherine M; Bland Lisa B; Hussain Maha; Goldman Bryan H; DeLoughery Thomas G; Crawford E David;
The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
Cancer 2006;107(3):489-96.
2006: Beer Tomasz M; Myrthue Anne
Calcitriol in the treatment of prostate cancer.
Anticancer research 2006;26(4A):2647-51.
2006: True Lawrence; Coleman Ilsa; Hawley Sarah; Huang Ching-Ying; Gifford David; Coleman Roger; Beer Tomasz M; Gelmann Edward; Datta Milton; Mostaghel Elahe; Knudsen Beatrice; Lange Paul; Vessella Robert; Lin Daniel; Hood Leroy; Nelson Peter S
A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(29):10991-6.
2006: Adams Greg; Mitchell Amanda; Ravichandran Ravi; Beer Tomasz M; Garzotto Mark
Metastatic adenocarcinoma of prostate in a healing sternotomy site.
Urology 2006;68(1):204.e13-5.
2006: Beer Tomasz M; Tangen Catherine M; Nichols Craig R; Margolin Kim A; Dreicer Robert; Stephenson William T; Quinn David I; Raghavan Derek; Crawford E David
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Cancer 2006;106(12):2624-9.
2006: Garzotto Mark; Myrthue Anne; Higano Celestia S; Beer Tomasz M
Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.
Urologic oncology 2006;24(3):254-9.
2006: Beer Tomasz M; Garzotto Mark; Park Byung; Mori Motomi; Myrthue Anne; Janeba Nicole; Sauer David; Eilers Kristine
Effect of calcitriol on prostate-specific antigen in vitro and in humans.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(9):2812-6.
2006: Spurgeon Stephen E F; Hsieh Yi-Ching; Rivadinera Adrianna; Beer Tomasz M; Mori Motomi; Garzotto Mark
Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy.
The Journal of urology 2006;175(3 Pt 1):918-22.
2006: Purnell Jonathan Q; Bland Lisa B; Garzotto Mark; Lemmon Dianne; Wersinger Emily M; Ryan Christopher W; Brunzell John D; Beer Tomasz M
Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer.
Journal of lipid research 2006;47(2):349-55.
2006: Beer Tomasz M; Bland Lisa B; Bussiere Joseph R; Neiss Michelle B; Wersinger Emily M; Garzotto Mark; Ryan Christopher W; Janowsky Jeri S
Testosterone loss and estradiol administration modify memory in men.
The Journal of urology 2006;175(1):130-5.
2006: Ganzini Linda; Beer Tomasz M; Brouns Matthew; Mori Motomi; Hsieh Yi-Ching
Interest in physician-assisted suicide among Oregon cancer patients.
The Journal of clinical ethics 2006;17(1):27-38.
2005: Bussiere Joseph R; Beer Tomasz M; Neiss Michelle B; Janowsky Jeri S
Androgen deprivation impairs memory in older men.
Behavioral neuroscience 2005;119(6):1429-37.
2005: Beer Tomasz M; Javle Milind; Lam Gilbert N; Henner W David; Wong Alvin; Trump Donald L
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7794-9.
2005: Garzotto Mark; Park Yon; Mongoue-Tchokote Solange; Bledsoe Jesse; Peters Laura; Blank Bruce H; Austin Donald; Beer Tomasz M; Mori Motomi
Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies.
Cancer 2005;104(9):1911-7.
2005: Beer Tomasz M
ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.
BJU international 2005;96(4):508-13.
2005: Janoff Daniel M; Peterson Chad; Mongoue-Tchokote Solange; Peters Laura; Beer Tomasz M; Wersinger Emily M; Mori Motomi; Garzotto Mark
Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
BJU international 2005;96(4):503-7.
2005: Tiffany Natasha M; Ryan Christopher W; Garzotto Mark; Wersinger Emily M; Beer Tomasz M
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
The Journal of urology 2005;174(3):888-92.
2005: Shannon Jackilen; Tewoderos Selome; Garzotto Mark; Beer Tomasz M; Derenick Rhianna; Palma Amy; Farris Paige E
Statins and prostate cancer risk: a case-control study.
American journal of epidemiology 2005;162(4):318-25.
2005: Stephenson Robert A; Mori Motomi; Hsieh Yi-Ching; Beer Tomasz M; Stanford Janet L; Gilliland Frank D; Hoffman Richard M; Potosky Arnold L
Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study.
The Journal of urology 2005;174(2):646-50; discussion 650.
2005: Wagner Matthew; Loos James; Weksler Nicole; Gantner Marin; Corless Christopher L; Barry John M; Beer Tomasz M; Garzotto Mark
Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Biochemical and biophysical research communications 2005;332(3):800-7.
2005: Garzotto Mark; Beer Tomasz M; Hudson R Guy; Peters Laura; Hsieh Yi-Ching; Barrera Eduardo; Klein Thomas; Mori Motomi
Improved detection of prostate cancer using classification and regression tree analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(19):4322-9.
2005: Devi Gayathri R; Beer Tomasz M; Corless Christopher L; Arora Vikram; Weller Doreen L; Iversen Patrick L
In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3930-8.
2005: Wagner Matthew; Garzotto Mark; Lemmon Dianne; Eilers Kristine M; Beer Tomasz M
Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.
Urology 2005;65(4):799.
2005: Strother John M; Beer Tomasz M; Dreicer Robert
Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?
European journal of cancer (Oxford, England : 1990) 2005;41(6):954-64.
2005: Beer Tomasz M; Myrthue Anne; Eilers Kristine M
Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.
World journal of urology 2005;23(1):28-32.
2005: Bland Lisa B; Garzotto Mark; DeLoughery Thomas G; Ryan Christopher W; Schuff Kathryn G; Wersinger Emily M; Lemmon Dianne; Beer Tomasz M
Phase II study of transdermal estradiol in androgen-independent prostate carcinoma.
Cancer 2005;103(4):717-23.
2004: Beer Tomasz M; Myrthue Anne; Garzotto Mark; O'hara Michael F; Chin Raymond; Lowe Bruce A; Montalto Michelle A; Corless Christopher L; Henner W David
Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(12):2225-32.
2004: Vetto John T; Beer Tomasz M; Fidda Nisreen; Ham Bruce; Jimenez-Lee Ricardo; Schmidt Waldemar
Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate cancer.
Diagnostic cytopathology 2004;31(6):417-9.
2004: Beer Tomasz M; Tangen Catherine M; Bland Lisa B; Thompson Ian M; Crawford E David
Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894.
The Journal of urology 2004;172(6 Pt 1):2213-7.
2004: Beer Tomasz M; Garzotto Mark; Katovic Nina M
High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer.
American journal of clinical oncology 2004;27(5):535-41.
2004: Beer T M; Garzotto M; Henner W D; Eilers K M; Wersinger E M
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.
British journal of cancer 2004;91(8):1425-7.
2004: Fromme Erik K; Eilers Kristine M; Mori Motomi; Hsieh Yi-Ching; Beer Tomasz M
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(17):3485-90.
2004: Tiffany N M; Wersinger E M; Garzotto M; Beer T M
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Urology 2004;63(5):934-9.
2004: Beer Tomasz M; Bubalo Joseph S
Prevention and management of prostate cancer chemotherapy complications.
The Urologic clinics of North America 2004;31(2):367-78.
2004: Beer Tomasz M; Myrthue Anne
Calcitriol in cancer treatment: from the lab to the clinic.
Molecular cancer therapeutics 2004;3(3):373-81.
2004: el-Geneidy M; Garzotto M; Panagiotou I; Hsieh Y C; Mori M; Peters L; Klein T; Beer T M
Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort.
BJU international 2004;93(4):510-5.
2004: Beer Tomasz M; Garzotto Mark; Lowe Bruce A; Ellis William J; Montalto Michelle A; Lange Paul H; Higano Celestia S
Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1306-11.
2004: Beer Tomasz M; Garzotto Mark; Eilers Kristi M; Lemmon Dianne; Wersinger Emily M
Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
Urology 2004;63(2):342-7.
2004: Beer Tomasz M; Eilers Kristine M; Garzotto Mark; Hsieh Yi-Ching; Mori Motomi
Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.
Cancer 2004;100(4):758-63.
2004: Evans Adam J; Henner William David; Eilers Kristi M; Montalto Michelle A; Wersinger Emily M; Andersen Peter E; Cohen James I; Everts Edwin C; McWilliams Jeffrey E; Beer Tomasz M
Polymorphisms of GSTT1 and related genes in head and neck cancer risk.
Head & neck 2004;26(1):63-70.
2004: Beer Tomasz M
Experimental use of GnRH antagonists as second-line hormonal therapy.
Reviews in urology 2004;6 Suppl 7():S33-8.
2004: Panagiotou Irene; Beer Tomasz M; Hsieh Yi-Ching; Mori Motomi; Peters Laura; Klein Thomas; Garzotto Mark
Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen.
Oncology 2004;67(3-4):194-202.
2003: Beer Tomasz M; Berry William; Wersinger Emily M; Bland Lisa B
Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.
Clinical prostate cancer 2003;2(3):167-72.
2003: Garzotto Mark; Hudson R Guy; Peters Laura; Hsieh Yi-Ching; Barrera Eduardo; Mori Motomi; Beer Tomasz M; Klein Thomas
Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Cancer 2003;98(7):1417-22.
2003: Beer Tomasz M
Development of weekly high-dose calcitriol based therapy for prostate cancer.
Urologic oncology 2003;21(5):399-405.
2003: Beer T M; Garzotto M; Henner W D; Eilers K M; Wersinger E M
Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
British journal of cancer 2003;89(6):968-70.
2003: Hoffelt S Christopher; Marshall Lynn M; Garzotto Mark; Hung Arthur; Holland John; Beer Tomasz M
A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer.
International journal of radiation oncology, biology, physics 2003;57(1):29-32.
2003: Beer Tomasz M
Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea.
Health news (Waltham, Mass.) 2003;9(8):1-2.
2003: Culkin Daniel J; Beer Tomasz M
Advanced penile carcinoma.
The Journal of urology 2003;170(2 Pt 1):359-65.
2003: Beer Tomasz M; El-Geneidi Mohammed; Eilers Kristine M
Docetaxel (taxotere) in the treatment of prostate cancer.
Expert review of anticancer therapy 2003;3(3):261-8.
2003: Beer Tomasz M; Garzotto Mark; Eilers Kristi M; Lemmon Dianne
Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
The Journal of urology 2003;169(5):1738-41.
2003: Rago Randall P; Einstein Albert; Lush Richard; Beer Tomasz M; Ko Yoo-Joung; Henner W David; Bubley Glenn; Merica Elizabeth A; Garg Varun; Ette Ene; Harding Matthew W; Dalton William S
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Cancer chemotherapy and pharmacology 2003;51(4):297-305.
2003: Beer Tomasz M; Lemmon Dianne; Lowe Bruce A; Henner W David
High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
Cancer 2003;97(5):1217-24.
2003: Beer Tomasz M; Eilers Kristine M; Garzotto Mark; Egorin Merrill J; Lowe Bruce A; Henner W David
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):123-8.
2003: Henner William David; Beer Tomasz M
A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer Therapy.
Reviews in urology 2003;5 Suppl 3():S38-44.
2002: Lavelle Michael; Schuff Kathyrn G; Keller Frederick S; Binkert Christoph A; O'Hara Michael; Fairfax Cynthia A; Beer Tomasz M
Unilateral autonomous testicular testosterone production mimicking androgen independent prostate cancer.
The Journal of urology 2002;168(3):1098-9.
2002: Beer Tomasz M; Bubalo Joseph S
Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.
Current urology reports 2002;3(3):232-8.
2002: Madison Dana L; Beer Tomasz M; Bliziotes Michael M
Acute estramustine-induced hypocalcemia unmasking severe vitamin D deficiency.
The American journal of medicine 2002;112(8):680-1.
2002: Hayes-Lattin Brandon M; Kovach Peter A; Henner W David; Beer Tomasz M
Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel.
Urology 2002;59(1):137.
2002: Beer T M; Evans A J; Hough K M; Lowe B A; McWilliams J E; Henner W D
Polymorphisms of GSTP1 and related genes and prostate cancer risk.
Prostate cancer and prostatic diseases 2002;5(1):22-7.
2001: Henner W D; Evans A J; Hough K M; Harris E L; Lowe B A; Beer T M
Association of codon 72 polymorphism of p53 with lower prostate cancer risk.
The Prostate 2001;49(4):263-6.
2001: Garzotto M; Beer T M
Syndrome of inappropriate antidiuretic hormone secretion: a rare complication of prostate cancer.
The Journal of urology 2001;166(4):1386.
2001: Beer T M; Pierce W C; Lowe B A; Henner W D
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(9):1273-9.
2001: Hayes-Lattin B M; Maziarz R T; Beer T M
Allogeneic stem-cell transplantation in renal-cell carcinoma.
Current oncology reports 2001;3(5):433-7.
2001: Beer T M; Hough K M; Garzotto M; Lowe B A; Henner W D
Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
Seminars in oncology 2001;28(4 Suppl 15):49-55.
2001: Beer T M; Bubalo J S
Complications of chemotherapy for prostate cancer.
Seminars in urologic oncology 2001;19(3):222-30.
2001: Beer T W; Shepherd P; Pullinger N C
p27 immunostaining is related to prognosis in malignant mesothelioma.
Histopathology 2001;38(6):535-41.
2001: Beer T M; Munar M; Henner W D
A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation.
Cancer 2001;91(12):2431-9.
2000: Beer T; Raghavan D
Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder.
The Prostate 2000;45(2):184-93.
2000: Beer T W; Shepherd P; Theaker J M
Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin.
Histopathology 2000;37(3):218-23.
2000: McWilliams J E; Evans A J; Beer T M; Andersen P E; Cohen J I; Everts E C; Henner W D
Genetic polymorphisms in head and neck cancer risk.
Head & neck 2000;22(6):609-17.
2000: Beer T W; Carr N J; Whittaker M A; Pullinger N
Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma.
Annals of diagnostic pathology 2000;4(3):143-8.
1999: Beer T W; Maidment G; Mikel J J; van Wyk Q; Pullinger N C
Cytological diagnosis of bronchopneumonia at post mortem.
Cytopathology : official journal of the British Society for Clinical Cytology 1999;10(6):402-10.
1999: Beer T W; Carr N J
Fibroepithelial polyps of the anus with epithelial vacuolation.
The American journal of surgical pathology 1999;23(4):488-9.
1998: Beer T W; Carr N J; Buxton P J
Thorotrast associated nodular regenerative hyperplasia of the liver.
Journal of clinical pathology 1998;51(12):941-2.
1998: Beer T W; Smith H R
Bullous pemphigoid associated with cutaneous leukocytoclastic vasculitis.
International journal of dermatology 1998;37(12):940-2.
1998: Beer T W; Theaker J M; Tulloch D N
Pseudomyxoma ovariilike posttherapeutic alteration in prostate adenocarcinoma.
Journal of clinical pathology 1998;51(11):878.
1998: Smith H R; Ashton R E; Beer T W; Theaker J M
Neutrophil-poor Sweet's syndrome with response to potassium iodide.
The British journal of dermatology 1998;139(3):555-6.
1998: Smith H R; Connor M P; Beer T W; Ashton R E
The use of polymerase chain reaction in New World cutaneous leishmaniasis.
The British journal of dermatology 1998;139(3):539-40.
1998: Beer T; Carr N J; Weller R O
Inflammatory pseudotumor of peripheral nerve.
The American journal of surgical pathology 1998;22(8):1035-6.
1998: Beer T W
Cancer among spouses: review of 195 couples.
Cancer 1998;83(3):591-2.
1998: Beer T W; Buchanan R; Matthews A W; Stradling R; Pullinger N; Pethybridge R J
Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype.
Human pathology 1998;29(3):246-51.
1995: Beer T W; Buchanan R; Buckley C H
Uterine stromal sarcoma following tamoxifen treatment.
Journal of clinical pathology 1995;48(6):596.

Sign-in to see more